Obesity is a condition that arrives when someone put on extra weight to a level so that it becomes a serious health condition and can endanger their health. Obesity is basically the result of eating too many calories without doing required physical activities. It is normally measured with help of BMI (Body Mass Index) i.e. ratio of your height to your body weight. BMI of more than 27 indicates that the person might be overweight and BMI of 30 or more is indication of being obese. Obesity Treatment
Obesity treatment can be done via number of ways like diet programmes, physical exercise and of course, prescription drugs like Acomplia, Xenical. Diet programmes and exercise do help in reducing weight buy it works slowly. On the other hand, prescription drugs like Acomplia, Xenical are faster ways to obesity treatment. These are manufactured by renowned pharmaceutical companies and clinically approved for use.
Acomplia (Rimonabant) for Obesity treatment
Acomplia is a prescription drug for obesity treatment. A French pharmaceutical firm, Sanoti-Aventis manufactures Acomplia slimming pills, which have been approved for sale in the UK and many European countries.
Acomplia contains Rimonabant as the active ingredient which works basically by reducing craving and urge to eat and produces a feeling of fullness. It basically acts as a cannabinoid type I (CB1) receptor and works in the brain to produce feelings of fullness even by eating less food. Acomplia works best if you maintain intake of healthy diet along with physical exercise.
Dosage of Acomplia
Acomplia comes in dose of 20mg and in tablet form. It should be taken once a day, in the morning before breakfast. Acomplia is a prescription drug, so you must consult some doctor before you chose to buy acomplia. Doctor’s recommendation is required to check suitability of drug to your current health condition and to avoid any side effects.
Benefits of Acomplia Rimonabant
Apart from helping to achieve weight loss in case of obesity, Acomplia also assists in smoking cessation. Acomplia also has been shown to help improve heart conditions. It also helps lowering the fat, improve cholesterol and sugar levels found in the body and this way it is also a help to diabetic patients. It is being said that Acomplia can help you lose weight and stop smoking simultaneously. The studies have shown dramatic positive results in both smokers and obese patients.
Side Effects of Acomplia
Like any other prescription medication, Acomplia too is associated with certain side effects. Common side effects, besides others, include depression, anxiety, nervousness, dizziness, memory loss, vomiting, Diarrhoea
Precautions to be taken
You also have the option of Acomplia online which contains some online process to get required prescription before you take Acomplia.
However they are certain precautions to be taken. It should not be taken by patients who have decreased liver and kidney function. Acomplia Rimonabant should not be taken by patients who have depressive disorders and people who take antidepressant medicines. Pregnant and breastfeeding women should avoid weight loss medicines to avoid any risk to mother and baby.
You can also buy acomplia online from some online licensed and reliable pharmacies or clinics. In that case, registered medical doctors from such pharmacies examine your condition based on information given by patient in online consultation form. Doctor issues the required prescription only if he finds it suitable for your health condition. However, it can not replace face to face consultation with doctor.
“Rimonabant may have a distinctive dual effect that could prove to be critical in helping patients to quit smoking while reducing the likelihood of weight gain.”
In both studies, side effects were relatively mild and transient, the most commonly cited being nausea and dizziness. In a press conference following the late-breaking sessions, Després likened the nausea symptoms to the feeling of having overeaten. In addition, Rimonabant had no significant impact on blood pressure, heart rate, or QT interval. Depression and anxiety measures were also similar between the rimonabant- and placebo-treated patients.
The rimonabant news seemed to catch cardiologists and other ACC attendees off-guard, many telling heartwire that they trully believe that Rimonabant it’s an amaizing drug with high hopes in treating many diseases.
Most of the people who work in the field of metabolic syndrome feel that obesity is not going to be able to be cured with one pill, that there are redundant systems in the brain for controlling appetite. But if you hit one, you may be able to do something positive, and it does seem like they’ve hit an important system.
Cigarette smoking and obesity are the leading causes of death in the US,” Dr Eric Westman (Duke Clinical Research Center, Durham, NC) reminded . “These very encouraging findings suggest that Rimonabant could become a widely used medical therapy.”
Rimonabant- a single drug for weight loss, smoking cessation, dyslipidemia, and metabolic syndrome sounds almost too good to be true, but two clinical trials presented at the American College of Cardiology . The first in a new class of drug, Rimonabant is a cannaboid receptor 1 (CB1) antagonist that appears to be taking meeting attendees by surprise.
“Results of this trial indicate that physicians may finally have a new tool to treat common, classic complications that are major risk factors for cardiovascular disease but that are too often treated in isolation, such as hypertension, dyslipidemia, and type 2 diabetes,”
“Rimonabant may be helpful in targeting the cause of those clustering abnormalitiesfor example, abdominal obesityhopefully improving our ability to better manage cardiovascular risk in an expanding proportion of our patients.”
“At a time when an estimated 50 million people may be affected by metabolic syndrome, this is good news,” Dr Sidney Smith (University of North Carolina, Chapel Hill) told heartwire.
A full 44% of subjects taking rimonabant for one year lost more than 20% of their body weight, compared with only 16.3% of those taking 5-mg rimonabant and 10.3% of placebo-treated subjects. The number of patients with metabolic syndrome at study onset dropped by more than 50% in the 20-mg patients.
A help for those who want to quit smoking :after 10 weeks of treatment, including a two-week run-in period when they were allowed to continue to smoke and a final four-week period when smoking abstinence was assessed, smokers randomized to 20 mg of rimonabant were twice as likely to quit as people randomized to placebo.
The advancement in medical science makes it possible to lose weight without indulging into any time spending exercises. A number of diet pills are available to treat excess body weight. Few of them are as under: -
• Rimonabant
• Phentermine
• Xenical
• Meridia and many more…
Rimonabant is one of the popular diet pills and is now available in the market of whole Europe to treat obesity. Rimonabant Acomplia can be an effectual way to lose weight and it may suppress your appetite rather than burning your body fat. Unlike any other appetite suppressant acomplia may show remarkable results when taken in conjunction with balanced diet and mild exercises. Rimonabant diet pill can also be used as an effective treatment for unhealthy smoking habits. This weight loss drug acts as a single medicine to treat both obesity and to quit smoking habit.
Medical experts have studied the side-effects of acomplia. The most common and side-effects of acomplia diet pills are as follows:
• Restlessness
• Irritability
• Depression
• Nausea
• Dizziness
However Acomplia have lesser side effects than other diet pills. It facilitates you to achieve remarkable benefits on weight loss, smoking cessation, blood sugar, and blood pressure.
It is advised to take acomplia diet pill by consulting your doctor. Your doctor may restrict you from taking acomplia if you have had serious health problem earlier.
You should follow the directions of your doctor while taking acomplia. It is of no use to take double dose of acomplia to gain quick results. However, it may harm your health.
You should take precautions while you consume rimonabant. Precautions are as easiest way to stay away from the harmful effects of any medicine.
While Merck is wrapping up a series of clinical trials of diet drug Taranabant, which it expects to submit for FDA approval later this year, Pfizer has just launched a new Phase III trial of its diet drug CP-945,598, suggesting it may be considerably further away from being brought to market.
Merck has two Phase III trials –one a two-year Phase III study involving 2,400 patients, the second a one-year Phase III study involving 1,000 patients — of taranabant, a CB-1 receptor inverse agonist, that appear to have been completed in the first two months of this year.
To this point, Merck has provided no information on the results of these studies — and for that matter, still has released no final information from a two-year, 2,400-patient Phase II study that was completed in December.
Meanwhile, Pfizer’s clinical trial program for its drug targeting the same receptor — which unlike taranabant, is a CB-1 receptor antagonist like rimonabant (Acomplia) — appears to be lagging significantly behind.
Pfizer seems to still be recruiting participants for its two-year Phase III study of CP-945,598 — which began back in 2006 — and lists the estimated completion date for this study as August 2009.
Moreover, Pfizer has only recently begun recruiting 850 participants for a one-year Phase III trial of CP-945,598 — which like the Merck one-year trial of taranabant is focused not on weight-loss but on the use of the drug to prevent weight-regain — and this trial is not set for completion until Jan. 2010.
The notoriously close-mouthed Pfizer also has provided no information on results of its earlier Phase II study of CP-945,598, which was completed more than two years ago.
Interestingly, however, both Merck and Pfizer have one-year Phase III studies underway of the use of their CB-1 drugs in treating type 2 diabetics.
The treatment of diabetes as well as obesity seems to be at the heart of the hopes of Sanofi-Aventis for a second try next year at U.S. approval of rimonabant. Sanofi withdrew its original application last summer after a U.S. FDA advisory panel expressed concern over the drug’s depressive side-effects.
